CATIE: Welcome to the real world

Actas Espanolas de Psiquiatria

Volumn 34, Issue 4, 2006, Pages 213-215

  Alvarez Martinez E ^a   Bernardo Arroyo, M ^b   Rocca Benassar, Miguel ^c  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT DE LES ILLES BALEARS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; EDITORIAL; HUMAN; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33746894616     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (8)

1. Gray GE. Evidence-based medicine: an introduction for psychiatrists. J Psychiatr Pract 2002;8:5-13.
2. Freemantle N, Blonde L, Bolinger B, Gerber RA, Hobbs FD. Real-world trials to answer real-world questions. Pharmacoeconomics 2005;23:747-54.
3. Seeman MV. Clinical trials in psychiatry: do results apply to practice? Can J Psychiatry 2001;46:352-5.
4. Gilbody S, Wahlbeck K, Adams C. Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand 2002;105:243-51.
5. Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing Clinical and Functional Outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. Schizophr Bull 2003;29:33-43.
6. Stroup TS, McEvoy JP, Swart M, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. Schizophr Bull 2003;29:15-31.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-23.
8. Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med 2005;353:1286-8.